Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon May 05, 2021 4:16pm
128 Views
Post# 33134296

RE:RE:RE:RE:RE:Don haut

RE:RE:RE:RE:RE:Don haut
JimmyJ wrote:
MrMugsy wrote:
Fotoforester wrote:
It means Don is a busy man. He's still on the Antibe advisory team as stated in the posted link. Doesn't mean anything to Antibe as he's been involved in multiple projects since the beginning, obviously.



Right - he's on the advisory board - working with a team of experts - all helping Dan.  Think it's a weekly chat group (in a way).

Don is certainly going to do other things beyond advising.

Question is ... any synergies between Antibe and Carmine ?


 

 

Is it a coincidence ATE tweeted this 6 days ago?   
https://twitter.com/antibethera/status/1387837851916722181?s=21

Could it be that was ATE letting the world know Don is still on the board, and the reminded the world prior to the announcement that Don is taking on a new CEO role.  It would be unprofessional for ATE to come out after the announcement saying Don is still in the board. I could be wrong but that's what my business spidy sense is telling me. 

BTW, Yukon you called it!  $4 is within site again :(
I thought for $5 was the bottom but I was wrong on that.  I am taking this as an opportunity to increase my position, as I see a lot more value coming down the pipeline.  My stance still remains all or nothing on this stock. 


 



It's an interesting question - I was thinking it was more about pointing how the depth of the advisory group.  Seems like lots have questions about Haut now regardless of the posting.

To be clear - advisory group continues as it is (Thanks to Marky's investigation).
<< Previous
Bullboard Posts
Next >>